Robert Hughes, Ph.D.

Robert Hughes, Ph.D., is EVP of Drug Discovery and Preclinical Development. Prior to joining Rectify, Robert was an Atlas EIR and head of molecular discovery at Disarm Therapeutics, which was acquired in 2020 by Eli Lily in a deal valued up to $1.36 billion. Robert has over 20 years of experience in drug discovery. Previously, Robert held positions at Boehringer-Ingelheim and Pfizer, working across multiple therapeutic areas, including cardiometabolism, neurodegeneration, and immunology, as well as target classes advancing programs from conception to the clinic. Robert is a co-author/co-inventor on more than 65 publications and patents. Robert received his Ph.D. in chemistry from the Scripps Research Institute with Professor KC Nicolaou and a B.S. degree in chemistry and mathematics from the University of Arizona.